Roche and Austria-based Hookipa Pharma tied up a licensing and research and development collaboration valued at more than $950 million focused on KRAS-mutated cancers.
https://www.pharmalive.com/wp-content/uploads/2021/03/Roche-Bolsters-Diagnostics-Pipeline-with-1.8-Billion-Buy-of-GenMark-BioSpace-3-15-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-20 18:28:172022-10-21 10:44:26Roche and Hookipa tie up in KRAS inhibitor deal valued at potential $950M
